RT Journal Article
SR Electronic
T1 Combined Impact of Prior SARS-CoV-2 Infection and Vaccination on Antibody Presence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21263268
DO 10.1101/2021.09.08.21263268
A1 Shuford, Jennifer A
A1 Swartz, Michael D
A1 Lakey, David L
A1 Aguillard, Kimberly A
A1 Pont, Stephen J
A1 Valerio-Shewmaker, Melissa A
A1 Boerwinkle, Eric
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263268.abstract
AB As COVID-19 continues to spread rapidly and vaccine uptake stagnates, questions remain about the amount of SARS-CoV-2 antibodies present in the population induced by either SARS-CoV-2 infection, by a COVID-19 vaccine, or both.The TEXAS Coronavirus Antibody REsponse Survey (CARES) is a statewide seroprevalence program which utilizes the Roche S-test to detect antibodies to the SARS-CoV-2 spike protein and the Roche N-test to detect antibodies to the SARS-CoV-2 nucleocapsid protein, to monitor the combined impact of prior infection and the COVID-19 vaccine. The current sample size having both S- and N-test data and reported vaccination status is 8,846.Participants with prior infection (i.e. N+) and with either partial or full vaccination have the highest proportion of those showing the maximum value of the S-test (80.95% and 83.07%, respectively). Using a permutation test, there is no statistically significant difference between the median S-test value for those that have had prior infection and are partially vaccinated versus those that have had prior infection and are fully vaccinated. These groups both show significantly higher median amount compared to the other three groups: N+/not vaccinated, N-/partially vaccinated, and N-/fully vaccinated (all p-values < 0.0001).Unvaccinated individuals with prior infection have one of the lowest median S-test values. For participants with previous SARS-CoV-2 infection and a COVID-19 vaccine, the median S-test value is high and is not statistically different between those who are partially vaccinated and those who are fully vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTexas Department of State Health Services (Contract #HHS000866600001) Texas Department of State Health Services had no role in the study design, data collection and analysis. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project has been approved by the UTHealth Committee for Protection of Human Subjects, IRB# HSC-SPH-20-0825.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTexas CARES investigators are committed to data sharing. Granular results and user-specified data summaries are currently publicly available on the Texas CARES portal. When baseline recruitment is complete, a deidentified individual level dataset will be available for download from the same portal. https://sph.uth.edu/projects/texascares/dashboard